The legal action involves claims that numerous manufacturers coordinated to fix prices, causing patients to pay more than necessary for their prescriptions. While the settlement with Glenmark provides an initial $20.7 million for distribution to purchasers, the litigation against two dozen other manufacturers—including Teva, Sandoz, and Pfizer—remains active. Officials expect the settlement fund to grow as cases against these non-settling defendants proceed. The current agreement does not address the safety or efficacy of the drugs, focusing exclusively on the financial impact of the alleged price-fixing scheme.

Eligibility depends on residency in a participating state or territory and the purchase of specific medications during the ten-year window. Claim forms are not yet available, but individuals are encouraged to register at AGGenericDrugs.com for updates on the distribution process. Those wishing to opt out of the current agreement must file their requests by October 15, 2026. The court is scheduled to hold a final approval hearing on November 5, 2026, to review the terms of the Glenmark settlement.